These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11798634)

  • 1. [The serum bactericidal activity of domestic fleroxacin and lomefloxacin].
    Zhao M; Jiang S; Wang R
    Zhonghua Nei Ke Za Zhi; 1999 Feb; 38(2):98-100. PubMed ID: 11798634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
    Beskid G; Prosser BL
    Am J Med; 1993 Mar; 94(3A):2S-8S. PubMed ID: 8383919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic effects of ciprofloxacin, fleroxacin and lomefloxacin in vivo and in vitro.
    Fuentes F; Martín MM; Izquierdo J; Gomez-Lus ML; Prieto J
    Chemotherapy; 1996; 42(5):354-62. PubMed ID: 8874975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Mycobacterium leprae activity of several quinolones studied in the mouse.
    Pattyn SR
    Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):613-7. PubMed ID: 1666402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro activities of newly developed quinolones, fleroxacin, lomefloxacin and sparfloxacin against Mycobacterium tuberculosis].
    Kawahara S; Kamisaka K; Tada A; Nakada H; Mishima Y; Yoshimoto S; Matsuyama T; Kibata M; Nagare J
    Kekkaku; 1991 Jun; 66(6):429-31. PubMed ID: 1942726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postantibiotic effect of ciprofloxacin compared with that of five other quinolones.
    Minguez F; Ramos C; Barrientos S; Loscos A; Prieto J
    Chemotherapy; 1991; 37(6):420-5. PubMed ID: 1760941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.
    Erwin ME; Jones RN
    J Clin Microbiol; 1992 May; 30(5):1170-3. PubMed ID: 1316366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of five fluoroquinolones on the bactericidal activity of human polymorphonuclear leukocytes against Staphylococcus aureus].
    Ballesta S; Pascual A; García I; Conejo C; Perea EJ
    Enferm Infecc Microbiol Clin; 1996 Dec; 14(10):600-3. PubMed ID: 9053002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
    Fernandes PB; Swanson RN
    Drugs Exp Clin Res; 1988; 14(6):375-8. PubMed ID: 3145851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activities of five quinolones against Chlamydia pneumoniae.
    Hammerschlag MR; Hyman CL; Roblin PM
    Antimicrob Agents Chemother; 1992 Mar; 36(3):682-3. PubMed ID: 1320366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae.
    Lemmen SW; Häfner H; Klik S; Lütticken R; Zolldann D
    Chemotherapy; 2003 May; 49(1-2):33-5. PubMed ID: 12714807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-resistance and cross-susceptibility between fluoroquinolone agents.
    Barry AL; Fuchs PC
    Eur J Clin Microbiol Infect Dis; 1991 Dec; 10(12):1013-8. PubMed ID: 1666360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MIC and disk diffusion quality control guidelines for Neisseria gonorrhoeae susceptibility tests of cefdinir, cefetamet, CI-960, fleroxacin, lomefloxacin, and temafloxacin.
    Erwin ME; Jones RN; Koontz FP; Gerlach EH; Murray PR; Washington JA
    J Clin Microbiol; 1992 May; 30(5):1317-9. PubMed ID: 1316371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of quinolones against slowly growing bacteria.
    Dalhoff A; Matutat S; Ullmann U
    Chemotherapy; 1995; 41(2):92-9. PubMed ID: 7758362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of E-4868, a new fluoroquinolone with a 7-azetidin ring, compared with ciprofloxacin, ofloxacin and fleroxacin.
    Mirelis B; Navarro F; Miró E; Coll R; Xicota MA; Prats G
    Drugs Exp Clin Res; 1995; 21(4):129-38. PubMed ID: 8529525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A clinical study in the treatment of acute bacterial infections with fleroxacin].
    Hou J; Li J; Cui H
    Zhonghua Nei Ke Za Zhi; 1996 Oct; 35(10):663-7. PubMed ID: 9592325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria.
    Piddock LJ; Panchal S; Norte V
    J Antimicrob Chemother; 1993 Jun; 31(6):855-63. PubMed ID: 8395493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.